Skip to main content
. 2017 Oct 7;8(61):103108–103116. doi: 10.18632/oncotarget.21600

Figure 1. Kaplan-Meier survival curves of prostate cancer patients treated with Lu-PSMA stratified by various prognostic variables in the multivariate analysis.

Figure 1

(A) a prostate-specific antigen (PSA) decline more than 14%. (B) Hb level prior to the first cycle. (C) AST level prior to the first cycle. (D) albumin level prior to the first cycle.